OptiNose (OPTN) & Its Peers Head-To-Head Review
OptiNose (NASDAQ: OPTN) is one of 189 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare OptiNose to similar businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, valuation, dividends and earnings.
This table compares OptiNose and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
48.0% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a summary of recent recommendations for OptiNose and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OptiNose currently has a consensus target price of $29.00, suggesting a potential upside of 59.87%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.62%. Given OptiNose’s stronger consensus rating and higher probable upside, analysts clearly believe OptiNose is more favorable than its competitors.
Earnings and Valuation
This table compares OptiNose and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|OptiNose Competitors||$217.29 million||-$39.39 million||-66.50|
OptiNose’s competitors have higher revenue, but lower earnings than OptiNose.
OptiNose beats its competitors on 6 of the 10 factors compared.
OptiNose Company Profile
OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation.
Receive News & Ratings for OptiNose Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose Inc and related companies with MarketBeat.com's FREE daily email newsletter.